CIA
BIB icon

Capital Investment Advisors’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Capital Investment Advisors’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$489K Hold
5,996
– – 0.01% 496
2025
Q4 		$478K Sell
5,996
-100
-2% -$7.4K 0.01% 493
2025
Q3 		$363K Sell
6,096
-200
-3% -$10.8K 0.01% 535
2025
Q2 		$288K Sell
6,296
-685
-10% -$30.2K 0.01% 580
2025
Q1 		$336K Sell
6,981
-3,015
-30% -$162K 0.01% 518
2024
Q4 		$506K Sell
9,996
-549
-5% -$32.5K 0.01% 418
2024
Q3 		$672K Hold
10,545
– – 0.01% 359
2024
Q2 		$625K Sell
10,545
-350
-3% -$19.4K 0.01% 360
2024
Q1 		$627K Sell
10,895
-430
-4% -$24.9K 0.01% 361
2023
Q4 		$646K Sell
11,325
-525
-4% -$24.6K 0.02% 337
2023
Q3 		$568K Sell
11,850
-1,050
-8% -$53.9K 0.02% 332
2023
Q2 		$671K Sell
12,900
-625
-5% -$34.4K 0.02% 299
2023
Q1 		$733K Sell
13,525
-270
-2% -$15.2K 0.02% 289
2022
Q4 		$796K Hold
13,795
– – 0.02% 277
2022
Q3 		$657K Sell
13,795
-300
-2% -$16K 0.02% 297
2022
Q2 		$682K Sell
14,095
-150
-1% -$7.63K 0.02% 302
2022
Q1 		$884K Buy
14,245
+185
+1% +$11.4K 0.03% 283
2021
Q4 		$1.14M Buy
14,060
+200
+1% +$17.1K 0.03% 254
2021
Q3 		$1.32M Buy
13,860
+78
+0.6% +$7.89K 0.04% 230
2021
Q2 		$1.36M Buy
13,782
+500
+4% +$43.6K 0.05% 225
2021
Q1 		$1.11M Buy
13,282
+14
+0.1% +$1.32K 0.04% 237
2020
Q4 		$1.15M Buy
13,268
+13
+0.1% +$1.01K 0.05% 223
2020
Q3 		$927K Buy
13,255
+835
+7% +$59.2K 0.04% 236
2020
Q2 		$902K Buy
12,420
+2,750
+28% +$176K 0.05% 233
2020
Q1 		$448K Buy
9,670
+225
+2% +$12.5K 0.03% 295
2019
Q4 		$583K Buy
9,445
+300
+3% +$16K 0.03% 301
2019
Q3 		$389K Sell
9,145
-500
-5% -$23.7K 0.02% 346
2019
Q2 		$500K Buy
9,645
+455
+5% +$22.6K 0.03% 312
2019
Q1 		$510K Buy
9,190
+130
+1% +$7K 0.03% 303
2018
Q4 		$381K Sell
9,060
-800
-8% -$41.7K 0.03% 327
2018
Q3 		$687K Buy
9,860
+875
+10% +$57.2K 0.04% 250
2018
Q2 		$514K Buy
8,985
+525
+6% +$28.6K 0.03% 289
2018
Q1 		$466K Buy
8,460
+3,850
+84% +$231K 0.03% 306
2017
Q4 		$258K Buy
4,610
+65
+1% +$3.67K 0.02% 407
2017
Q3 		$278K Buy
+4,545
New +$258K 0.02% 382

Other funds holding BIB

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KFS
Kaizen Financial Strategies Campbell, California $308M AUM 41.73% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return
CAG
Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.79B AUM 27.94% 1-Year Est. Return

Capital Investment Advisors's BIB Position: Q1 2026 in Review

Capital Investment Advisors held its ProShares Ultra NASDAQ Biotechnology (BIB) position steady in Q1 2026 at 5,996 shares worth $489K. The position accounts for 0.01% of the portfolio, ranked #496.

Capital Investment Advisors first reported a position in BIB in Q3 2017 and has held it in 35 quarters since. The position peaked at $1.36M in Q2 2021. 23 funds tracked by Wall St. Rank hold BIB as of Q1 2026.

  • Capital Investment Advisors held 5,996 shares of ProShares Ultra NASDAQ Biotechnology worth $489K as of Q1 2026.
  • Capital Investment Advisors left its ProShares Ultra NASDAQ Biotechnology share count unchanged in Q1 2026.
  • ProShares Ultra NASDAQ Biotechnology made up 0.01% of Capital Investment Advisors's portfolio in Q1 2026, its #496 holding.
  • Capital Investment Advisors first reported a position in ProShares Ultra NASDAQ Biotechnology in Q3 2017 and has held it in 35 quarters since.
  • Capital Investment Advisors's ProShares Ultra NASDAQ Biotechnology position peaked at $1.36M in Q2 2021.
  • 23 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2026.

Based on Capital Investment Advisors's 13F filing for Q1 2026, filed 16 Apr 2026.